metformin
DrugOral administration, 500 mg daily at week 1. Every week metformin dosage increases with 500 mg, to a maximum dose of 1000 mg bid. This maximum dose will be administered till the end of the study.
Other names: Glucophage
NCT Number: NCT01487993
The purpose of this study is to determine whether metformin is effective in reducing BMI and insulin resistance in obese children and adolescents.
Looking for future studies?
Notify Me10 year–16 year
All sexes
Interventional
Phase 3
Jeroen Bosch Hospital, 's-Hertogenbosch, Netherlands
The prevalence of obesity in children and adolescents is increasing rapidly and is associated with significant medical and psychosocial consequences persisting into adulthood.
Obesity may lead to metabolic complications, such as insulin resistance, which can progress via impaired fasted glucose and impaired glucose tolerance to type 2 diabetes mellitus (T2DM) and to the development of micro- and macro-vascular complications.
Metformin, an oral anti-diabetic licensed for T2DM for adults and children from 10 years onwards, is already used off label in obese children and adolescents with insulin resistance, even though the specific effects of metformin in these obese children and adolescents have not been elucidated, particularly upon long-term use.
The rationale for this study is based on the hypothesis that metformin may reduce body mass index (BMI), insulin resistance and percentage of body-fat in obese children and adolescents with insulin resistance. Further more it is anticipated that metformin may delay the progression to T2DM and thereby micro- and macro-vascular complications in obese children and adolescents with insulin resistance.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Oral administration, 500 mg daily at week 1. Every week metformin dosage increases with 500 mg, to a maximum dose of 1000 mg bid. This maximum dose will be administered till the end of the study.
Other names: Glucophage
Lifestyle intervention: 18 months physical therapy and dietary advice
Time frame: 18 months and 36 months
Change in BMI after part 1 (double blind) and part 2 ( follow-up)
Time frame: 3; 6; 9; 12; 15; 18; 24; 30 and 36 months
calculated by the Homeostasis Model Assessment for Insulin Resistance (HOMA-IR).
Time frame: 3; 6; 9; 12; 15; 18; 24; 30 and 36 months
creatinine and alat
Time frame: 3; 6; 9; 12; 15; 18; 24; 30 and 36 months
The amount of reported adverse effects, in relation to the achieved dose level.
Time frame: 9 months
Clearance where applicable expressed per body weight, age category, Tanner Stage and gender, clearance will be determined with a two-compartment pharmacokinetic model using non linear mixed effect modelling.
Time frame: 0, 9, 18 and 36 months
Time frame: 0, 9, 18 and 36 months
Time frame: 0, 9, 18 and 36 months
Time frame: 36 months
Based on BMI and HOMA-IR values
Time frame: 36 months
Renal and hepatic function after 36 months of metformin use
Time frame: 36 months
The amount of adverse effects after 36 months
Time frame: 36 months
Measured as micro-albuminuria
Time frame: 36 monthts
Measured with Pulse Wave Velocity and Augmentation Index.
Time frame: 36 months
Time frame: 9 months
Volume of distribution, where applicable expressed per body weight, age category, Tanner Stage and gender, volume of distribution will be determined with a two-compartment pharmacokinetic model using non linear mixed effect modelling.
St. Antonius Hospital
Other
An Efficacy, Safety and Pharmacokinetic Study on the Short-term and Long-term Use of Metformin in Obese Children and Adolescents
Acronym: MetVoorMin
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01809288
Behavior, Body Weight
Bethesda, Maryland, United States
View Trial DetailsNCT00340132
Body Weight, Body Weight Changes
Phoenix, Arizona, United States
View Trial DetailsNCT07701005
Body Weight, Digestive System Diseases
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT03627104
Body Weight, Glucose Metabolism Disorders
Mexico City, Mexico
View Trial Details